With a direct focus on Streptococcus pneumoniae, this fraction shows outstanding inhibition, providing a potential solution for challenging respiratory infections and pneumonias. Additionally, its ability to inhibit Streptococcus agalactiae and Cryptococcus neoformans opens new opportunities for treating neonatal infections and complications in immunocompromised patients. The selectivity and potency of this fraction make it a promising candidate for the development of new antimicrobial treatments.
Know more about the pathogens